Bryn Mawr Capital Management LLC Grows Position in Becton, Dickinson and Company (NYSE:BDX)

Bryn Mawr Capital Management LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 224.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,185 shares of the medical instruments supplier's stock after purchasing an additional 16,034 shares during the quarter. Bryn Mawr Capital Management LLC's holdings in Becton, Dickinson and Company were worth $5,260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Alberta Investment Management Corp grew its stake in shares of Becton, Dickinson and Company by 12.4% during the 4th quarter. Alberta Investment Management Corp now owns 22,700 shares of the medical instruments supplier's stock worth $5,150,000 after acquiring an additional 2,500 shares during the period. Legacy Solutions LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $226,000. Global Retirement Partners LLC grew its stake in shares of Becton, Dickinson and Company by 126.4% during the 4th quarter. Global Retirement Partners LLC now owns 6,008 shares of the medical instruments supplier's stock worth $1,363,000 after acquiring an additional 3,354 shares during the period. Northcape Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 0.7% during the 4th quarter. Northcape Wealth Management LLC now owns 9,763 shares of the medical instruments supplier's stock worth $2,215,000 after acquiring an additional 69 shares during the period. Finally, Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $25,000. Institutional investors own 86.97% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BDX shares. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, February 12th. Finally, Barclays increased their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $278.29.

Insider Activity

In related news, Director Jeffrey William Henderson purchased 1,500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, February 10th. The shares were acquired at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the transaction, the director now directly owns 8,015 shares in the company, valued at $1,872,464.30. The trade was a 23.02 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roland Goette sold 4,483 shares of the firm's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares in the company, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,544 shares of company stock worth $2,370,309. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded down $0.33 on Friday, hitting $227.61. The company's stock had a trading volume of 812,368 shares, compared to its average volume of 2,050,808. The company has a 50-day simple moving average of $232.86 and a 200 day simple moving average of $233.34. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a market capitalization of $65.35 billion, a PE ratio of 37.82, a PEG ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.83%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback program on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.